Literature DB >> 2990057

In-vitro studies with SF 86-327, a new orally active allylamine derivative.

S Shadomy, A Espinel-Ingroff, R J Gebhart.   

Abstract

SF 86-327 (Sandoz Forschungsinstitut) is an orally active allylamine derivative related to naftifine. The antifungal activity of SF 86-327 was compared in vitro with those of naftifine, ketoconazole, and itraconazole (R 51,211, Janssen Pharmaceutica) by agar dilution. 120 fungal isolates were tested. Also, the antifungal activities of SF 86-327 and naftifine against 18 dimorphic pathogens were assayed in vitro by broth dilution. Results of these studies support claims that SF 86-327 is a broad spectrum antifungal agent. Results of the broth dilution studies also revealed that SF 86-327 was both fungistatic and fungicidal in vitro for isolates of Blastomyces dermatitidis, Histoplasma capsulatum and Sporothrix schenckii at concentrations as low as 0.05 micrograms ml-1 (18 isolates tested, MIC90 = 0.39 micrograms ml-1, MFC90 = 12.5 micrograms ml-1).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990057     DOI: 10.1080/00362178585380201

Source DB:  PubMed          Journal:  Sabouraudia        ISSN: 0036-2174


  18 in total

1.  Pharmacokinetics of oral terbinafine in horses and Greyhound dogs.

Authors:  M M Williams; E G Davis; B KuKanich
Journal:  J Vet Pharmacol Ther       Date:  2011-06       Impact factor: 1.786

Review 2.  Naftifine. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses.

Authors:  J P Monk; R N Brogden
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

3.  Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy.

Authors:  P E Verweij; N J Cox; J F Meis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

Review 4.  In vitro and in vivo evaluation of antifungal agents.

Authors:  A Espinel-Ingroff; S Shadomy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

5.  In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts.

Authors:  N S Ryder; S Wagner; I Leitner
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  Bioassay for SF 86-327, a new antifungal agent.

Authors:  V L Kan; D K Henderson; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

7.  Antifungal activity of the allylamine derivative terbinafine in vitro.

Authors:  G Petranyi; J G Meingassner; H Mieth
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

8.  MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp.

Authors:  H J Schmitt; E M Bernard; J Andrade; F Edwards; B Schmitt; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

Review 9.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 10.  Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.

Authors:  J A Balfour; D Faulds
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.